Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients
- 28 February 2005
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 41 (3) , 386-392
- https://doi.org/10.1016/j.ejca.2004.10.019
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trialsThe Lancet Oncology, 2003
- Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanomaMelanoma Research, 2003
- Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanomaBritish Journal of Cancer, 2003
- Prolonged Survival After Complete Resection of Disseminated Melanoma and Active Immunotherapy With a Therapeutic Cancer VaccineJournal of Clinical Oncology, 2002
- Final Version of the American Joint Committee on Cancer Staging System for Cutaneous MelanomaJournal of Clinical Oncology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Surgical treatment of metastatic melanomaThe American Journal of Surgery, 1998
- Clinical and prognostic relevance of serum S‐100β protein in malignant melanomaBritish Journal of Dermatology, 1998
- Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysisCancer, 1993
- Surgery as Palliative Treatment for Distant Metastases of MelanomaAnnals of Surgery, 1986